Today’s medicines can cost hundreds of thousands of dollars a year. The story of how two companies set prices for their costly new drugs suggests that the way we determine the value of such treatments will help decide the future of our health-care system.
Biotech startup Greenlight Biosciences has a cell-free approach to microbial chemical production.
Scientists use immune cells to smuggle molecules across the blood-brain barrier in the hopes of treating neurodegenerative diseases.
World’s largest smartphone chipmaker offers to custom-build very efficient neuro-inspired chips for phones, robots, and vision systems.
Several gene therapies are or will soon be in late-stage human trials. One of them could be the first to get FDA approval for sale in the U.S.
Despite promising results in controlling neuronal activity, leaders in brain research still wrestle over turning their work into treatments.
Notre Dame researchers will test a concussion-detection app on nearly a thousand high school and youth football players.
Researchers are using smart helmets and imaging to study brain injury risk in young football players over a season.
New research indicates that chemical fingerprints can make positive matches between batches of sarin.
By studying the interactions between our bodies and our microbes, a startup hopes to find new ways of treating disease.